Key Segmentation:
By Service Type
-
Bioanalytical Testing
-
Method Development and Validation
-
Stability Testing
-
Raw Material Testing
-
Microbial Testing
-
Extractables and Leachables Testing
-
Other Services
By End User
-
Pharmaceutical and Biopharmaceutical Companies
-
CDMOs and CROs
-
Medical Device Companies
-
Academic and Research Institutes
By Technology
-
Chromatography-Based Testing
-
Mass Spectrometry
-
Molecular and Immunoassay Testing
-
Spectroscopy
-
Cell-Based Bioassays
-
Other Technologies
By Development Phase
-
Preclinical and Phase I
-
Phase II
-
Phase III
-
Commercial and Quality Control Release
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Eurofins Scientific, SGS, Charles River Laboratories, Labcorp, WuXi AppTec, Thermo Fisher Scientific, Pace Life Sciences, Frontage Laboratories, Pharmaron, NAMSA, Nelson Labs, ALS Limited, TÜV SÜD, Solvias and Alcami.
Key opportunities include cell and gene therapy testing, medical device chemical characterization, extractables and leachables studies and expansion of capacity in Asia Pacific.
The growing complexity of biologics and advanced therapies, together with outsourcing by drug developers, is the main growth factor.
By Service Type, the Bioanalytical Testing segment dominated the market in 2025 with an estimated 29.88% share, supported by pharmacokinetic and immunogenicity studies for new drugs.
North America dominated the market with a share of 40.74% in 2025, driven by a large drug development pipeline, a mature laboratory sector and strict regulatory standards.